May 28, 2019 04:10PM
May 13, 2019 08:00AM
Apr 16, 2019 08:09AM
Apr 16, 2019 08:00AM
Apr 12, 2019 08:00AM
Apr 10, 2019 04:07PM
Apr 10, 2019 04:07PM Rexahn Announces Reverse Stock Split
Mar 27, 2019 08:00AM
Mar 8, 2019 08:00AM
Mar 4, 2019 08:14AM
Mar 4, 2019 08:00AM
Mar 1, 2019 08:00AM
Feb 19, 2019 08:08AM
Feb 19, 2019 08:00AM Rexahn Presents Updated Interim Data From Phase 2a Trial of RX-3117 in Advanced Bladder Cancer at the 2019 ASCO GU Symposium
Feb 6, 2019 08:00AM
Feb 4, 2019 08:00AM
Jan 23, 2019 09:02AM
Jan 23, 2019 09:00AM
Jan 22, 2019 04:42PM
Jan 22, 2019 04:42PM
Jan 22, 2019 07:36AM Rexahn Pharma (RNN) Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer at ASCO GI
Jan 22, 2019 07:30AM
Jan 14, 2019 08:00AM
Dec 6, 2018 08:00AM
Dec 3, 2018 08:00AM
Nov 14, 2018 08:05AM
Nov 14, 2018 08:00AM
Nov 5, 2018 08:00AM Rexahn Reports Third Quarter 2018 Financial Results
Oct 17, 2018 09:03AM
Oct 17, 2018 09:00AM
Oct 2, 2018 08:06AM
Oct 2, 2018 08:00AM
Sep 18, 2018 08:00AM
Aug 30, 2018 08:00AM
Aug 21, 2018 08:07AM Rexahn (RNN) Enters Pact with Merck (MRK) to Evaluate RX-5902 in combination with KEYTRUDA for Triple Negative Breast Cancer
Aug 21, 2018 08:00AM
Aug 7, 2018 08:00AM
Aug 6, 2018 08:00AM
Jun 14, 2018 10:00AM
Jun 4, 2018 08:03AM
Jun 4, 2018 08:00AM
May 15, 2018 08:06AM Rexahn Pharma (RNN) Announces its Phase 2a Combination Study of RX-3117 and Abraxane in First-line Metastatic Pancreatic Cancer Patients Advances to Second Stage
May 15, 2018 08:00AM
May 7, 2018 08:00AM
Apr 26, 2018 08:00AM
Mar 13, 2018 08:00AM
Mar 12, 2018 08:00AM
Feb 12, 2018 08:11AM
Feb 12, 2018 08:00AM Rexahn Reports Data from the Ongoing Phase 2a Clinical Trial of RX-3117 in Advanced Bladder Cancer at the American Society of Clinical Oncology Genitourinary Cancers (ASCO GU) 2018 Annual Meeting
Feb 8, 2018 08:00AM

322,246 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All